Immunovant (NASDAQ:IMVT – Get Free Report) had its target price increased by Truist Financial from $30.00 to $48.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price target suggests a potential upside of 37.46% from the company’s previous close. A number of […]
Immunovant to Present at Upcoming Investor Conferences tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Immunovant, Inc (IMVT) Reports In-Line Q2 EPS streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Immunovant (NASDAQ:IMVT – Get Free Report) and Vericel (NASDAQ:VCEL – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability. Earnings & Valuation This table compares Immunovant and Vericel’s gross […]